Related Experiment Videos
[Clinical trial on ibandronate in patients with tumor-associated hypercalcemia]
Tao Wang1, San-tai Song, Ze-fei Jiang
1Department of Breast Cancer, Hospital Affiliated to Academy of Military Medical Sciences, Beijing 100039, China.
Objective:
Ibandronate, a third generation bisphosphonate, inhibits bone resorption in human and animal studies. This study is to evaluate the efficacy and safety of ibandronate as a single agent in patients with tumor-associated hypercalcemia.
Methods:
An open, multicenter, non-controlled clinical trial was conducted in 22 patients. The patients received 2 mg ibandronate intravenously if the corrected calcium was less than 3.0 mmol/L but more than 2.7 mmol/L; they received 4 mg ibandronate iv if corrected calcium was more than 3.0 mmol/L.
Results:
There was 100% efficacy in these two dose groups but the calcium correcting effect was more pronounced in the 4-mg dose group than the 2-mg dose group. The most common adverse reactions were fever and skin itching with an incidence of 4.5%.
Conclusion:
Ibandronate is active in patients with tumor-associated hypercalcemia and the adverse effects are well tolerated.